| Transport for abciximab facilitated primary angioplasty versus on-site thrombolysis with a liberal rescue policy: the randomised Holland Infarction Study (HIS). | |
| | |
MedLine Citation:
|
PMID: 16786231 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: As of to date, the only large transportation trial comparing on-site fibrin-specific thrombolysis with transfer for primary angioplasty in patients presenting in a referral centre is the DANAMI-2 trial, with only 3% rescue angioplasty. The Holland Infarction Study (HIS) compared abciximab facilitated primary angioplasty (FP) with on-site fibrin-specific thrombolytic therapy (TT) with a liberal protocol-driven rescue angioplasty (transport to intervention centre in case < 50% ST resolution at 60 min). METHODS AND RESULTS: Patients in a referral centre without shock and < 4.5 h of chest pain presenting with ST-elevation having > or = 12 mm ST-segment shift were randomised to either strategy. Of the originally planned 900 patients only 48 were included due to suspension of financial funding. Death, recurrent MI and stroke at one year was 8% for the FP-group and 22% for the TT-group (p = 0.2). Two hours after randomisation the rates of complete ST-segment resolution (> or =70%) were 52% and 35%, respectively (p = 0.2). CONCLUSION: This prematurely discontinued randomised transportation trial shows favorable trends with respect to long-term clinical outcome and early ST-resolution for abciximab facilitated primary angioplasty. In view of the real world delays associated with interhospital transport for primary angioplasty, treatment strategies focusing on early fibrin-specific lysis with a liberal selective rescue policy are warranted. |
| | |
Authors:
|
Hendrik-Jan Dieker; Elvira V van Horssen; Ferry M R J Hersbach; Marc A Brouwer; Ad J van Boven; Arnoud W J van 't Hof; Wim R M Aengevaeren; Freek W A Verheugt; Frits W H M Bär |
Publication Detail:
|
Type: Comparative Study; Journal Article; Meta-Analysis; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of thrombosis and thrombolysis Volume: 22 ISSN: 0929-5305 ISO Abbreviation: J. Thromb. Thrombolysis Publication Date: 2006 Aug |
Date Detail:
|
Created Date: 2006-06-20 Completed Date: 2006-10-02 Revised Date: 2007-08-27 |
Medline Journal Info:
|
Nlm Unique ID: 9502018 Medline TA: J Thromb Thrombolysis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 39-45 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. h.dieker@cardio.umcn.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty* Antibodies, Monoclonal / therapeutic use* Female Fibrinolytic Agents / therapeutic use* Humans Immunoglobulin Fab Fragments / therapeutic use* Male Middle Aged Myocardial Infarction* / drug therapy, mortality, surgery Netherlands Outcome Assessment (Health Care) Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Thrombolytic Therapy* / mortality Transportation of Patients* Treatment Failure |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Fibrinolytic Agents; 0/Immunoglobulin Fab Fragments; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 143653-53-6/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: m...
Next Document: Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST ...